GeneDx beat Q2 estimates, raised guidance, and is seeing rapid test volume growth and stronger reimbursements. Check out why ...

That earnings report, unveiled well before market open that day, revealed that GeneDx booked nearly $103 million in revenue.

The most assertive raise of the three came from BTIG's Mark Massaro, who now feels GeneDx is worth $125 per share, well up ...

Shares in genetic testing company GeneDx Holdings (NASDAQ: WGS) continued their wild ride in 2025 and are up almost 34% on the week to Friday morning. This week's move follows the American Academy ...

GeneDx has robust de-identified data from more than 700,000 exome and genome results that can help researchers better understand gene-disease relationships for patients with seizures.

GeneDx published data in JAMA from a cohort of more than 1300 patients with CP and found that exome and genome sequencing delivered a more than 30% diagnostic rate for these patients.

STAMFORD, Conn., March 14, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced its scientific contributions at ...

Lavelle TA, Feng X, Keisler M, et al. Cost-effectiveness of exome and genome sequencing for children with rare and undiagnosed conditions. Genet Med. 2022;24 (6):1349-1361. doi: 10.1016/j.gim.2022 ...